Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
Shionogi Co., Ltd announced it will invest USD 2.1 billion to increase its stake in ViiV Healthcare...
Shionogi
Shionogi’s Fetroja Wins China NMPA Approval for Complicated UTIs, Targets Resistant Gram‑Negative Infections
Shionogi Co., Ltd announced that China’s National Medical Products Administration (NMPA) has granted marketing approval...
Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma
Shionogi & Co., Ltd. (Japan) announced it will acquire 100% of the shares of a...
CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...
BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections
Swiss biopharma BioVersys AG (SWX: BIOV) announced a research and exclusive license option agreement with...
Shionogi Partners with Link Medical for Cefiderocol Development in Australia and New Zealand
Japan-based Shionogi Co., Ltd. has entered into an exclusive licensing agreement with Link Medical Products...
Shionogi Submits Rolling NDA for Ensitrelvir in US for COVID-19 Prophylaxis
Shionogi announced on April 1, 2025, the initiation of a rolling New Drug Application (NDA)...
Kelun Pharmaceutical’s Generic Mulpleta Gains NMPA Approval in China
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that it has received marketing...
Sino Biopharmaceutical’s Chia Tai Tianqing Secures Exclusive Promotion Rights for Naldemedine in China
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced an exclusive market promotion agreement between its...
Vocabria Receives Positive CHMP Opinion for HIV Treatment in Adolescents
GSK plc (NYSE: GSK) has announced that ViiV Healthcare, an HIV specialist majority owned by...
Shionogi Files for Chinese Approval of Cefiderocol to Combat Gram-Negative Bacterial Infections
Shionogi Co., Ltd, a prominent Japanese pharmaceutical company, has announced the filing of a New...
Shionogi’s Xofluza Gains Approval in Taiwan for Pediatric Influenza Treatment and Prophylaxis
Shionogi & Co., Ltd, a leading Japanese pharmaceutical company, has announced that it has received...
Shionogi’s Acquisition of Qpex Impacts Brii Biosciences’ Rights to Anti-infective Drugs
Japan’s Shionogi & Co., Ltd (TYO: 4507) announced on June 26, 2023, its planned acquisition...
Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing...
Shanghai Pharmaceuticals Secures Exclusive Rights for Shionogi’s Ensitrelvir in China
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced an import and distribution agreement with Japan-based...
Hansoh Pharma Licenses GHDDI’s GDI-4405 for Global Development in COVID-19
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with the Global...
Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China
Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National...